Trial Profile
Feasibility Pilot Study of OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Disufenton (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 31 Oct 2023 Planned End Date changed from 30 Jun 2025 to 1 Nov 2025.
- 31 Oct 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Apr 2024.
- 31 Oct 2023 Status changed from recruiting to active, no longer recruiting.